<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="0" ids="37733">Cholinesterase inhibitors</z:chebi> and memantine do not have regulatory approval in most of the world for treatment of vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>A systematic review and meta-analysis was undertaken to assess the evidence for efficacy and safety of <z:chebi fb="0" ids="37733">cholinesterase inhibitors</z:chebi> and memantine in vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: PubMed, BIOSIS, International Pharmaceutical Abstracts, and Cochrane registries were searched for randomised, placebo-controlled trials on <z:chebi fb="0" ids="37733">cholinesterase inhibitors</z:chebi> and memantine in patients with vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Trial methods, clinical characteristics, outcomes, and adverse events were extracted and checked </plain></SENT>
<SENT sid="4" pm="."><plain>Meta-analytic methods using fixed-effects models were used to give summaries of each drug's effects </plain></SENT>
<SENT sid="5" pm="."><plain>FINDINGS: Three <z:chebi fb="0" ids="53289,53290,53292">donepezil</z:chebi>, two galantamine, one rivastigmine, and two memantine trials, comprising 3093 patients on the study drugs and 2090 patients on placebo, met the selection criteria </plain></SENT>
<SENT sid="6" pm="."><plain>Trials were of 6-month duration with similar vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> criteria and outcome measures </plain></SENT>
<SENT sid="7" pm="."><plain>Cognitive effects on the <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's Disease</z:e> Assessment scale were significant for <z:hpo ids='HP_0000001'>all</z:hpo> drugs, ranging from a -1.10 point mean difference (95% CI -2.15 to -0.05) for rivastigmine to -2.17 for 10 mg daily <z:chebi fb="0" ids="53289,53290,53292">donepezil</z:chebi> (95% CI -2.98 to -1.35) </plain></SENT>
<SENT sid="8" pm="."><plain>Only 5 mg daily <z:chebi fb="0" ids="53289,53290,53292">donepezil</z:chebi> had an effect on the Clinicians' Global Impression of Change scale (odds ratio 1.51 [95% CI 1.11-2.07]) </plain></SENT>
<SENT sid="9" pm="."><plain>No behavioural or functional benefits were observed, except for a -0.95 point difference (95% CI -1.74 to -0.16) with 10 mg daily <z:chebi fb="0" ids="53289,53290,53292">donepezil</z:chebi> on the <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's Disease</z:e> Functional Assessment and Change Scale </plain></SENT>
<SENT sid="10" pm="."><plain>Compared with placebo, more dropouts and adverse events (<z:hpo ids='HP_0002039'>anorexia</z:hpo>, <z:hpo ids='HP_0002018'>nausea</z:hpo>, <z:hpo ids='HP_0002013'>vomiting</z:hpo>, diarrhoea, and <z:hpo ids='HP_0100785'>insomnia</z:hpo>) occurred with the <z:chebi fb="0" ids="37733">cholinesterase inhibitors</z:chebi>, but not with memantine </plain></SENT>
<SENT sid="11" pm="."><plain>INTERPRETATION: <z:chebi fb="0" ids="37733">Cholinesterase inhibitors</z:chebi> and memantine produce small benefits in cognition of uncertain clinical significance in patients with mild to moderate vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>Data are insufficient to support widespread use of these drugs in vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="13" pm="."><plain>Individual patient analyses are needed to identify subgroups of patients with vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> who might benefit </plain></SENT>
</text></document>